MX391749B - Formulaciones de esferas farmacéuticas que comprenden dimetilfumarato - Google Patents
Formulaciones de esferas farmacéuticas que comprenden dimetilfumaratoInfo
- Publication number
- MX391749B MX391749B MX2018009749A MX2018009749A MX391749B MX 391749 B MX391749 B MX 391749B MX 2018009749 A MX2018009749 A MX 2018009749A MX 2018009749 A MX2018009749 A MX 2018009749A MX 391749 B MX391749 B MX 391749B
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical
- dimethyl fumarate
- composition
- formulations
- bead composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 9
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 title abstract 3
- 229960004419 dimethyl fumarate Drugs 0.000 title abstract 3
- 239000011324 bead Substances 0.000 abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 238000013270 controlled release Methods 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662294054P | 2016-02-11 | 2016-02-11 | |
| PCT/US2017/016934 WO2017139331A1 (en) | 2016-02-11 | 2017-02-08 | Pharmaceutical bead formulations comprising dimethyl fumarate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018009749A MX2018009749A (es) | 2019-02-07 |
| MX391749B true MX391749B (es) | 2025-03-21 |
Family
ID=58057304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018009749A MX391749B (es) | 2016-02-11 | 2017-02-08 | Formulaciones de esferas farmacéuticas que comprenden dimetilfumarato |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11033509B2 (https=) |
| EP (1) | EP3413879A1 (https=) |
| JP (2) | JP6902043B2 (https=) |
| KR (1) | KR20180108814A (https=) |
| CN (1) | CN108778256A (https=) |
| AU (1) | AU2017217464B2 (https=) |
| CA (1) | CA3013472A1 (https=) |
| EA (1) | EA201891803A1 (https=) |
| IL (1) | IL261073A (https=) |
| MA (1) | MA44010A (https=) |
| MX (1) | MX391749B (https=) |
| WO (1) | WO2017139331A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3013472A1 (en) * | 2016-02-11 | 2017-08-17 | Biogen Ma Inc. | Pharmaceutical bead formulations comprising dimethyl fumarate |
| EP4090315A1 (en) * | 2020-01-17 | 2022-11-23 | Société des Produits Nestlé S.A. | Dosage form with sustained release melatonin pellets |
| US20240269084A1 (en) | 2021-06-04 | 2024-08-15 | Zim Laboratories Limited | Delayed release compositions of dimethyl fumarate |
| CN115300616A (zh) * | 2022-08-24 | 2022-11-08 | 韩永刚 | 一种单胃动物用的肠溶葡萄糖氧化酶固体分散体 |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2316430T3 (pl) * | 2004-10-08 | 2012-11-30 | Forward Pharma As | Kompozycje farmaceutyczne o kontrolowanym uwalnianiu, zawierające ester kwasu fumarowego |
| US20080187579A1 (en) | 2007-02-01 | 2008-08-07 | Pavan Bhat | Extended-release dosage form |
| CN114146081A (zh) * | 2012-02-07 | 2022-03-08 | 比奥根玛公司 | 含有富马酸二甲酯的药物组合物 |
| WO2015042294A1 (en) * | 2013-09-18 | 2015-03-26 | Xenoport, Inc. | Nanoparticle compositions of dimethyl fumarate |
| US10172794B2 (en) * | 2013-12-13 | 2019-01-08 | Biogen Ma Inc. | Controlled release dosage form for once daily administration of dimethyl fumarate |
| MA40982A (fr) * | 2014-11-19 | 2017-09-26 | Biogen Ma Inc | Formulation de bille pharmaceutique comprenant du fumarate de diméthyle |
| MX387092B (es) * | 2015-06-17 | 2025-03-19 | Biogen Ma Inc | Particulas de dimetilfumarato y composiciones farmaceuticas de estas. |
| CN104971048B (zh) * | 2015-07-01 | 2019-01-18 | 上海汇伦医药科技有限公司 | 富马酸二甲酯肠溶微丸及其制备方法 |
| CA3013472A1 (en) * | 2016-02-11 | 2017-08-17 | Biogen Ma Inc. | Pharmaceutical bead formulations comprising dimethyl fumarate |
-
2017
- 2017-02-08 CA CA3013472A patent/CA3013472A1/en active Pending
- 2017-02-08 WO PCT/US2017/016934 patent/WO2017139331A1/en not_active Ceased
- 2017-02-08 MA MA044010A patent/MA44010A/fr unknown
- 2017-02-08 EP EP17706072.0A patent/EP3413879A1/en not_active Withdrawn
- 2017-02-08 MX MX2018009749A patent/MX391749B/es unknown
- 2017-02-08 AU AU2017217464A patent/AU2017217464B2/en not_active Expired - Fee Related
- 2017-02-08 US US16/076,849 patent/US11033509B2/en not_active Expired - Fee Related
- 2017-02-08 KR KR1020187025947A patent/KR20180108814A/ko not_active Ceased
- 2017-02-08 JP JP2018542269A patent/JP6902043B2/ja not_active Expired - Fee Related
- 2017-02-08 CN CN201780016727.0A patent/CN108778256A/zh active Pending
- 2017-02-08 EA EA201891803A patent/EA201891803A1/ru unknown
-
2018
- 2018-08-09 IL IL261073A patent/IL261073A/en unknown
-
2021
- 2021-05-13 US US17/319,694 patent/US20210369629A1/en not_active Abandoned
- 2021-06-18 JP JP2021101599A patent/JP2021152050A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017217464B2 (en) | 2022-11-10 |
| JP6902043B2 (ja) | 2021-07-14 |
| AU2017217464A1 (en) | 2018-08-30 |
| EP3413879A1 (en) | 2018-12-19 |
| JP2019504859A (ja) | 2019-02-21 |
| KR20180108814A (ko) | 2018-10-04 |
| MX2018009749A (es) | 2019-02-07 |
| US20190046456A1 (en) | 2019-02-14 |
| CA3013472A1 (en) | 2017-08-17 |
| US20210369629A1 (en) | 2021-12-02 |
| IL261073A (en) | 2018-10-31 |
| CN108778256A (zh) | 2018-11-09 |
| JP2021152050A (ja) | 2021-09-30 |
| EA201891803A1 (ru) | 2019-01-31 |
| WO2017139331A8 (en) | 2017-10-12 |
| US11033509B2 (en) | 2021-06-15 |
| WO2017139331A1 (en) | 2017-08-17 |
| MA44010A (fr) | 2018-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022008662A2 (es) | Degradadores de smarca y usos de los mismos | |
| CL2020000075A1 (es) | Carboxamidas como moduladores de los canales de sodio. | |
| MX391749B (es) | Formulaciones de esferas farmacéuticas que comprenden dimetilfumarato | |
| MX2017016509A (es) | Particulas de dimetilfumarato y composiciones farmaceuticas de estas. | |
| SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
| MX2020013853A (es) | Compuestos innovadores. | |
| MA40240B1 (fr) | Composés hétéroaryle d'inhibition de la kinase | |
| BR112017022584A2 (pt) | regime para tratamento dos cabelos com o uso de um condicionador concentrado de espuma em aerossol | |
| CY1124338T1 (el) | Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων | |
| JOP20190107A1 (ar) | مثبطات أحادي أسيل جليسرول ليباز (magl) | |
| MX2019014041A (es) | Inhibidores pirazolicos de magl. | |
| MX2022006817A (es) | Formulaciones/composiciones que comprenden un inhibidor de btk. | |
| BR112019001768A2 (pt) | moduladores do receptor de spiro-lactamas nmda e usos dos mesmos | |
| CL2020002624A1 (es) | Formulaciones de inmunoconjugado anti-cd79b estables. | |
| BR112021019070A2 (pt) | Ligantes de pseudoquinase tyk2 | |
| CR20190536A (es) | Inhibidores pirazólicos de magl | |
| CO2020005485A2 (es) | Administración oral de análogos del péptido glp-1 | |
| MX375377B (es) | Formulación de perlas de cisteamina de liberación retardada. | |
| MX392182B (es) | Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| AU2016380190A8 (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof | |
| MX387731B (es) | Composiciones farmacéuticas orales de mesalazina. | |
| EA201791113A1 (ru) | Фармацевтические составы в виде гранул, содержащие диметилфумарат | |
| WO2018183631A8 (en) | Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same | |
| BR112021021060A2 (pt) | Anticorpos anti-cd38 e formulações | |
| CY1125399T1 (el) | Διαρυλικες συνθεσεις και μεθοδοι για τη διαμορφωση ενος καταρρακτη κινασης |